BioSpace News Archive

Drug Development

CVS Health Banks on Trust to Increase Diversity in Clinical Trials

CVS Health has seen about 40% patient diversity in the work it has done so far, Josh Rose, VP and head of decentralized clinical trials, site solutions and strategy told BioSpace.

June 20, 2022
·
5 min read
·
Gail Dutton
New Research Could Lead to Improved Therapies for Traumatic Brain Injury

New research conducted by scientists at UC Irvine shines new light on understanding traumatic brain injuries.

June 20, 2022
·
2 min read
·
Alex Keown
FDA

CDC Advisors Unanimous on Another COVID-19 Vaccine Option for Kids 6-17

Thursday, a committee of advisors for the CDC voted unanimously for children and teens, ages six to 17 to receive Moderna’s COVID-19 vaccine.

June 20, 2022
·
3 min read
·
Hayley Shasteen & Geoff Herman
Drug Development

Rain Targets Normal p53 Expression with Possible Pan-Cancer Therapeutic

In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, milademetan, and a pivotal readout for its Phase III trial of the same compound.

June 20, 2022
·
4 min read
·
Gail Dutton
Policy

France Aims to Become European Leader in Life Sciences Innovation

The government of France launched its Healthcare Innovation 2030 strategy that aims to turn the country into a European innovation leader within the next eight years.

June 20, 2022
·
3 min read
·
Alex Keown
Drug Development

AbbVie’s Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn’s Disease

The FDA’s decision is based on positive results from two induction and one maintenance clinical study of AbbVie’s Skyrizi for Crohn’s disease.

June 20, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine

Pfizer inked an Equity Subscription Agreement with France-based Valneva. They also updated their Collaboration and License deal for a Lyme disease vaccine that was announced in April.

June 20, 2022
·
3 min read
·
Mark Terry
Drug Development

Scholar Rock Sees Modest Improvements in Phase II SMA Study

Extension data from the Phase II TOPAZ trial showed that apitegromab yielded sustained and continued benefits in non-ambulatory patients with types 2 and 3 spinal muscular atrophy (SMA).

June 20, 2022
·
3 min read
·
Tristan Manalac
Hospital Supplies Market Demand, Insights and Forecast up to 2026

Wilmington, Delaware, United States: The global hospital supplies market may have grown steadily over the years, due to the rapid developments in the healthcare sector.

June 20, 2022
·
5 min read
Home Care Market is Expected to Witness Significant Growth between 2019 – 2029

Wilmington, Delaware, United States: Presence of a seamless industry for geriatric healthcare has played a crucial role in driving sales across the global home care market.

June 20, 2022
·
5 min read